康希诺:公司DTcP-Hib-MCV4联合疫苗产品在临床方案中已对相关免疫程序的最新适配予以考虑

互动易
03 Mar

有投资者向康希诺提问, 请问贵公司一个问题,贵公司的全球创新品种五联苗获批临床,但问题是贵公司的三组分百白破疫苗2月龄开打,Hib免疫程序也是2月龄开打,但奇怪的是贵公司的四价流脑结合疫苗是三月龄开打,那么问题来了,贵公司五联苗是2月龄开打还是3月龄开打?如果是3月龄开打,又有何竞争优势?再者贵公司的五联大概什么时候开始临床?谢谢。公司回答表示,尊敬的投资人您好,感谢您的关注及专业提问。公司...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10